Hyperion DeFi (HYPD) Q3 2024 earnings summary

Executive summary

• Significant progress in transforming into a leader in topical ophthalmic medications using Optejet technology, with commercial launches of MydCombi and clobetasol, and pipeline advancements including MicroPine for pediatric myopia.

• Expanded manufacturing capabilities, received FDA approval for MydCombi facility, and entered new collaborations for dry eye therapeutics targeting a $5 billion global market.

• First commercial sale of clobetasol propionate ophthalmic suspension 0.05% in September 2024, the first new ophthalmic steroid in over 15 years.

• Advanced Phase III CHAPERONE study of MicroPine, with interim analysis planned this quarter and potential entry into a multi-billion-dollar market.

• Board leadership transition and appointment of new CFO; received Nasdaq notice for minimum bid price non-compliance.

Financial highlights

• Net loss for Q3 2024 was $7.9 million ($0.11 per share), compared to $7.3 million ($0.18 per share) in Q3 2023; nine-month net loss was $29.9 million.

• Gross loss for Q3 2024 was $131,000, mainly due to inventory write-downs related to MydCombi and Gen 1 device.

• Q3 2024 revenue was $2,000, with nine-month revenue at $29,243; reflects early-stage commercialization and sampling strategy.

• Unrestricted cash at September 30, 2024, was $7.2 million, down from $14.8 million at year-end 2023.

• Working capital deficit of $4.1 million and accumulated deficit of $175.4 million as of September 30, 2024.

Outlook and guidance

• Anticipating Phase III CHAPERONE trial data readout for MicroPine this quarter; positive results could accelerate NDA filing to early 2026.

• Planning FDA submission for Gen-2 Optejet with MydCombi in 2025 and possible approval in 2026.

• Substantial doubt exists about ability to continue as a going concern without additional capital; may need to curtail R&D or reduce costs if funding is not secured.

• Ongoing evaluation of capital raising structures and long-term financing options to support strategy and loan obligations.

• Expecting positive margins from clobetasol sales to offset losses from Gen 1 device as commercialization expands.